G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 109 filers reported holding G1 THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.76 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $480,220 | -75.2% | 210,623 | -53.0% | 0.00% | – |
Q1 2024 | $1,935,192 | +5435.6% | 447,961 | +3808.2% | 0.00% | – |
Q4 2023 | $34,959 | +49.0% | 11,462 | -29.6% | 0.00% | – |
Q3 2023 | $23,459 | -90.2% | 16,291 | -83.1% | 0.00% | – |
Q2 2023 | $239,329 | +45.7% | 96,116 | +56.8% | 0.00% | – |
Q1 2023 | $164,257 | -88.7% | 61,290 | -77.1% | 0.00% | – |
Q4 2022 | $1,454,274 | +34993.5% | 267,822 | -19.3% | 0.00% | -100.0% |
Q3 2022 | $4,144 | +146.7% | 331,830 | -2.4% | 0.00% | – |
Q2 2022 | $1,680 | -100.0% | 340,034 | -23.6% | 0.00% | -100.0% |
Q1 2022 | $3,383,000 | -13.7% | 445,137 | +15.9% | 0.00% | 0.0% |
Q4 2021 | $3,920,000 | -57.5% | 383,952 | -44.2% | 0.00% | -50.0% |
Q3 2021 | $9,229,000 | -5.1% | 687,704 | +55.1% | 0.00% | 0.0% |
Q2 2021 | $9,725,000 | -29.3% | 443,259 | -22.5% | 0.00% | -33.3% |
Q1 2021 | $13,758,000 | -18.6% | 571,795 | -39.1% | 0.00% | -25.0% |
Q4 2020 | $16,902,000 | +53.1% | 939,561 | -1.7% | 0.00% | +33.3% |
Q3 2020 | $11,042,000 | +81.0% | 956,001 | +280.1% | 0.00% | +50.0% |
Q2 2020 | $6,102,000 | +167.2% | 251,515 | +21.3% | 0.00% | +100.0% |
Q1 2020 | $2,284,000 | -50.3% | 207,278 | +19.3% | 0.00% | 0.0% |
Q4 2019 | $4,592,000 | -21.8% | 173,752 | -32.6% | 0.00% | -50.0% |
Q3 2019 | $5,870,000 | +53.4% | 257,692 | +106.5% | 0.00% | +100.0% |
Q2 2019 | $3,826,000 | +100.3% | 124,799 | +8.5% | 0.00% | 0.0% |
Q1 2019 | $1,910,000 | +11.5% | 115,053 | +28.6% | 0.00% | 0.0% |
Q4 2018 | $1,713,000 | -63.7% | 89,468 | -0.8% | 0.00% | 0.0% |
Q3 2018 | $4,715,000 | +180.0% | 90,173 | +132.8% | 0.00% | – |
Q2 2018 | $1,684,000 | +124.5% | 38,741 | +91.4% | 0.00% | – |
Q1 2018 | $750,000 | +33.5% | 20,242 | -28.5% | 0.00% | – |
Q4 2017 | $562,000 | +168.9% | 28,308 | +237.6% | 0.00% | – |
Q3 2017 | $209,000 | -81.7% | 8,385 | -87.2% | 0.00% | – |
Q2 2017 | $1,144,000 | – | 65,575 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |